Reading...
Play button
Play button
Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
34 Cards in this Set
- Front
- Back
|
Mycophenolate Mofetil
|
converted to MPA to inhibit IMPDH, dec. guanine, inc. adenosine
lowers adhesion molecules, apoptosis in activated T-cells prevent acute organ transplant rejection (better than AZA), RA, lupus nephritis, psoriasis |
|
|
Sodium Mycophenolate
|
converted to MPA to inhibit IMPDH, dec. guanine, inc. adenosine
lowers adhesion molecules, apoptosis in activated T-cells prevent acute organ transplant rejection (better than AZA), RA, lupus nephritis, psoriasis |
|
|
Azathioprine
|
6-MP prodrug, inhibits IMP conversion to IMODH and forms 6-TG to disrupt DNA synthesis dec. IgG and IL-2
renal transplant (worse than MMF), RA, lupus, Behcet's disease slow release, so less toxic and longer lasting |
|
|
6-Mercaptopurine
|
inhibits IMP conversion to IMODH and forms 6-TG to disrupt DNA synthesis dec. IgG and IL-2
renal transplant (worse than MMF), RA, lupus, Behcet's disease Preferred as anti-neoplastic |
|
|
Methotrexate
|
Inhibits DHFR to stop denovo purine synthesis, adenosine builds up, apoptosis in T-cells and dec. adhesion
RA and psoriasis careful in liver disease & alcoholism |
|
|
Leflunomide
|
Inhibits pyrimidine synthesis and blocks dihydroorotate dehydrogenase to dec B and T cells
RA |
|
|
Cyclophosphamide
|
alkylates DNA to decrease B-cells but inc. T-cell proliferation
systemic lupus |
|
|
Cyclosporine A
|
Inhibits calcineurin, no NFAT phosphorylation and no IL-2 production and blunts anti-apoptotic proteins
organ transplant, psoriasis, RA, keratoconjunctivitis sicca |
|
|
Tacrolimus
|
Inhibits calcineurin, no NFAT phosphorylation and no IL-2 production and blunts anti-apoptotic proteins and binds FKBP to inhibit inflammatory mediators
organ transplant, eczema 50-100x more potent than CSA |
|
|
Everolimus
|
binds FKBP and inhibits mTOR, T-cell arrests in G1, IL-2 is inhibited
kidney/liver transplants |
|
|
Sirolmus
|
binds FKBP and inhibits mTOR, T-cell arrests in G1, IL-2 is inhibited
organ transplant, CAD elutingstent NO nephrotoxicity |
|
|
Etanercept
|
TNF-alpha and beta inhibitor through complement activation fusion protein
RA, PSA, kids >2 yo, plaque psoriasis, spondylitis |
|
|
Infliximab
|
Chimeric IgG mAb TNF-a inhibitor through complement activation
RA, plaque psoriasis, spondylitis, Chron's |
|
|
Adalimumab
|
Recombinant IgG mAb TNF-a inhibitor through complement activation
RA, PSA, kids >4 yo, plaque psoriasis, spondylitis, chron's |
|
|
Golimumab
|
Recombinant IgG mAb TNF-a inhibitor NO compliment activation
RA, PSA, spondylitis ***CAN use with other non-biologic DMARDS, NSAIDS, corticosteroids |
|
|
Certolizumab Pegol
|
Recombinant humanized Fab fragment from e. coli NO complement activation
RA and Chron's disease |
|
|
Tocilizumab
|
recombinant IL-6
RA, kids >2 yo **monitor LFT, platelets, neurtophils, lipids |
|
|
Anakinra
|
Recombinant IL-1 from e. coli blocks IL-1b from accessing receptor
RA, CAPS, NOMID, dec. bony erosions |
|
|
Rilonacept
|
Fusion protein of IL-1 and IgG
CAPS, FCAS, MWS, kids >12 yo **monitor lipids, LFT's |
|
|
Canakinumab
|
Recombinant anti-human IL-1 mAb
CAPS, FCAS, MWS, kids >4 yo **monitor LFT's |
|
|
Ustekinumab
|
Human IgG 1a mAb, preventing IL-12 & 2 activity
plaque psoriasis |
|
|
Tofacitinib
|
JAK 1&3 inhibitor to block IL 2,4,7,9,15,21
RA pts intolerant to MTX ***monitor LFT, platelets, neutrophils, lipids |
|
|
Belimumab
|
Human IgG gamma, blocks BLyS and BAFF
systemic lupus ***WORSE than Rituximab |
|
|
Antithymocyte Globulin (ATG)
|
gamma globulin from human thymocytes in all T-cells
organ transplant can cause cytokine release syndrome |
|
|
Muromonab CD3
|
mouse mAb, binds e-chain to activate complement and phagocytosis of T-cells
2nd line organ transplant when CSA fails **cytokine release syndrome |
|
|
Rituximab
|
chimeric antibody to CD on B-cells causing lysis
2nd line RA less risk of infection |
|
|
Basiliximab
|
chimeric blocker of CD25 on T-cells with MHC antigen stimulation
Acute organ rejection prophylaxis w/ CSA/glucocorticoids |
|
|
Daclizumab
|
humanized blocker of CD25 on T-cells with MHC antigen stimulation
Acute organ rejection prophylaxis w/ CSA/glucocorticoids |
|
|
Alemtuzumab
|
humanized, binds CD52 on T&B cells
lymphocytic leukemia |
|
|
Alefacept
|
human fusion binds CD2 to inhibit T-cells
plaque psoriasis |
|
|
Abatecept
|
binds B7 on APC to block T-cell activation
RA |
|
|
Efalizumab
|
no longer allowed in US
|
|
|
Natalizumab
|
humanized, inhibits movement of immune cells to inflammed site
VCAM-1 is MS madCAM-1 is Chrons causes PML blackbox |
|
|
Eculizumab
|
blocks C5 and MAC to decrease lysing of RBC's
PNH, atypical hemolytic-uremic syndrome |
